CXCR7 Modulators Piperazine Core Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, inflammatory diseases, and stem cell mobilization lack effective inhibitors for the CXCR7 receptor, which plays a crucial role in tumor growth, metastasis, and stem cell mobilization, and existing antagonists have limitations in specificity and efficacy.
Innovation Solution
Development of novel compounds that specifically bind to the CXCR7 receptor, inhibiting the binding of SDF-1 and I-TAC, thereby preventing tumor proliferation, metastasis, and modulating stem cell mobilization, which are administered in pharmaceutical compositions with pharmaceutically acceptable excipients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antagonists are used to inhibit CXCR7, then some therapeutic effect is achieved, but specificity and efficacy are limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures (R1, R2, R3, R4, R5, R6 substituents on the piperazine ring and aromatic groups) to optimize both binding affinity and specificity for CXCR7. This involves changing physical-chemical parameters such as molecular weight, lipophilicity, and electrostatic properties to achieve better therapeutic efficacy while maintaining high specificity.
Solution Approach 2:
The invention applies local quality by introducing specific substituent patterns at different positions of the piperazine core structure. Each position (R1-R6) is independently optimized to interact with specific regions of the CXCR7 binding pocket, thereby enhancing both specificity and efficacy through localized structural modifications rather than uniform changes.
2Measurement precision
If novel compounds are developed to improve specificity for CXCR7, then binding precision is enhanced, but development complexity increases
Solution Approach 1:
The patent applies universality by designing a piperazine-based core structure that serves as a universal scaffold for multiple CXCR7 antagonists. This core structure with its six substitutable positions (R1-R6) can accommodate various aromatic and heteroaromatic groups, allowing a single molecular framework to achieve multiple specificities and efficacies against CXCR7 while simplifying the overall development process.
3Reliability
If compounds are designed to inhibit tumor growth and metastasis, then therapeutic effectiveness is improved, but potential side effects on normal cells may increase
Solution Approach 1:
The patent applies the intermediary principle by designing compounds that specifically target the CXCR7 receptor as an intermediate between the drug and the pathological processes of tumor growth and metastasis. By achieving high binding specificity for CXCR7, the compounds act as selective mediators that interrupt cancer-related signaling pathways while minimizing interactions with receptors on normal cells, thereby reducing side effects.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Compounds having formula (I) or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.